Citations

Clear

3030 citation(s) found for "Susan, M".

A multiparameter classifier to predict response to lapatinib plus trastuzumab (LT) without chemotherapy in HER2+ breast cancer (BC).
Weigelt, Britta , Rexer, Brent N. , Forero‐Torres, Andres , Nanda, Rita , Storniolo, Anna Maria , Krop, Ian E. , Osborne, C. Kent , Veeraraghavan, Jamunarani , Gutiérrez, Carolina , Angelis, Carmine De , Wang, Tao , Pascual, Tomás , Galvan, Patricia , Wolff, Antonio C. , Goetz, Matthew P. , Reis‐Filho, Jorge S. , Hilsenbeck, Susan Galloway , Prat, Aleix , Schiff, Rachel , Rimawi, Mothaffar F.

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: 1011-1011

10.1200/jco.2020.38.15_suppl.1011 Get It

1011 Background: Several trials have shown 25-30% pathologic complete response (pCR) rates in patients with HER2+ BC treated with LT therapy (+ endocrine therapy if ER+), but no chemotherapy (CTX). We hypothesize that a multiparameter classifier, comprised of HER2 gene and protein levels, intratumor heterogeneity (ITH), HER2-enriched (E) subtype, and PIK3CA mutation status can identify patients whose tumors are “addicted” to HER2 signaling and are likely to achieve pCR from a CTX-sparing de-escalation strategy. Methods: Baseline specimens from 2 trials (TBCRC023 [NCT00999804] and PAMELA [NCT01973660]) of neoadjuvant CTX-sparing LT (+ endocrine therapy if ER+) in HER2+ BC were used. HER2 protein and ITH (scored for % 3+ by IHC), and gene amplification (HER2:CEP17 ratio and copy number (CN) by CISH) were measured on the same slide by the dual gene protein assay (GPA). HER2-E and PIK3CA mutation status were assessed by research-based PAM50 and MSK-IMPACT platforms, respectively. A decision tree algorithm was used to determine the GPA cutoffs and to construct the classifier of response (by pCR) in TBCRC023, which was then validated in PAMELA. Results: Of the evaluable patients from TBCRC023 (N = 130) and PAMELA (N = 151), GPA data were available for 121 and 94 cases, respectively. Both cohorts exhibited similar distributions for HER2 ratio, CN, and % 3+, and a strong correlation between HER2 ratio and CN (R > 0.92). In TBCRC023, 73 cases had data from GPA, PAM50, and IMPACT, of which 15 had pCR. Recursive partitioning identified cutoffs of HER2 ratio > 4.6 and % 3+ > 97.5% in both the GPA data cohort (N = 121) and complete data cohort (N = 73). With PAM50 and IMPACT data, the model added HER2-E and PIK3CA wild-type (wt). For practical reasons, the classifier was locked as HER2 ratio ≥ 4.5 AND % 3+ ≥ 90% AND PIK3CA-wt AND HER2-E, which yielded a PPV of 55% and NPV of 94%. Validation in PAMELA using 45 cases with data for all 3 assays yielded PPV of 44% and NPV of 82%. 29 TBCRC023 cases without IMPACT data could be predicted to be non-pCR, of which 26 were correct (NPV = 89%). In PAMELA, 66 additional cases could be predicted to be non-pCR, of which 54 were correct (NPV = 81%). Conclusions: We have constructed a multiparameter classifier that can predict pCR with targeted therapy alone that compare to pCR rates of CTX + dual anti-HER2 in unselected patients. Prospective validation in a clinical trial is warranted. [Table: see text]
Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practice
Koehler, Amber B. , Leung, Nelson , Call, Timothy G. , Rabe, Kari G. , Achenbach, Sara J., Leis, José F., Muchtar, Eli , Hayman, Suzanne R. , Hampel, Paul J. , Finnes, Heidi D. , Schwager, Susan M., Kenderian, Saad S. , Muchtar, E , Hampel, Paul J , Parikh, Sameer A , Chaffee, Kari G. , Leung, Nelson , Ding, Wei , Wang, Yucai , Slager, Susan L. , Kay, Neil E. , Parikh, Sameer A.

Mayo Clinic

Leukemia & Lymphoma | May 25, 2020 | Volume: 61 | Issue: 10 | Pages: 2383-2388

10.1080/10428194.2020.1768384 | PMID 32449401 Get It

Impact of COVID-19 on Pain Medicine Fellowship Training
Hagedorn, Jonathan M. , Moeschler, Susan M. , Furnish, Timothy , Durbhakula, Shravani , Moeschler, Susan, Hagedorn, Jonathan M , Sayed, Dawood

Mayo Clinic

Regional Anesthesia & Pain Medicine | May 23, 2020 | Volume: 46 | Issue: 2 | Pages: 188.2-189

10.1136/rapm-2020-101534 | PMID 32345656 Get It

Access to proton beam therapy (PBT) for patients with large mediastinal adenopathy (LMA)
Vega, Raymond B. Mailhot , Hoppe, BS, Charpentier, AM, Kessel, Sandy, Pei, Q., Keller, FG, Parsons, SK, Kelly, KM, Castellino, S, Mailhot Vega, Raymond B , Hodgson, David , FitzGerald, Thomas J. , Pei, Q, Parsons, Susan K. , Castellino, Sharon M.

Mayo Clinic

Klinische Pädiatrie | May 11, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0040-1701902 Get It

Cost-effectiveness of proton therapy for young adults with mediastinal lymphoma: analysis of an institutional cohort
Vega, Raymond B. Mailhot , Patel, Sumit , Bates, J.E., Lynch, James, Bansal, Megha , Slayton, William B. , Parsons, SK, Hoppe, BS, Mendenhall, NP, Mailhot Vega, Raymond B , Parsons, Susan K. , Mendenhall, NP

Mayo Clinic

Klinische Pädiatrie | May 11, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0040-1701885 Get It

A Proposed Shared Vision for Leadership Development for all Medical Students: A Call from a Coalition of Diverse Medical Schools
Mangrulkar, Rajesh S. , Tsai, Antonius, Cox, Susan M. , Nesse, Robert E., Silvestri, Ronald C. , Radabaugh, Carrie L., Skochelak, Susan E., Dallaghan, Gary L. Beck , Steiner, Beat , Cox, Susan M , Silvestri, Ronald C , Beck Dallaghan, Gary L , Steiner, Beat , Halaas, Gwen Wagstrom , Nelson, Elizabeth A.

Mayo Clinic

Teaching and Learning in Medicine | May 3, 2020 | Volume: 32 | Issue: 5 | Pages: 561-568

10.1080/10401334.2020.1754835 | PMID 32363950 Get It

Maintaining High-Quality Multidisciplinary Pain Medicine Fellowship Programs: Part II: Innovations in Clinical Care Workflow, Clinical Supervision, Job Satisfaction, and Postgraduation Mentorship for Pain Fellows During the COVID-19 Pandemic
Kohan, Lynn , Sobey, Christopher M., Wahezi, Sayed , Brancolini, Scott, Przkora, Rene , Shaparin, Naum , Spektor, Boris , Moeschler, Susan M. , Anițescu, Magdalena , Moeschler, Susan

Mayo Clinic

Pain Medicine | May 1, 2020 | Volume: 21 | Issue: 8 | Pages: 1718-1728

10.1093/pm/pnaa176 | PMID 32379882 Get It

Abstract Background Pain fellowship programs are facing unique challenges during the COVID-19 pandemic. Restrictions by state governments and the Centers for Disease Control and Prevention have resulted in a rapidly changing and evolving learning environment for today’s fellows. Innovative solutions must be sought to maintain proper education and ensure the well-being of our trainees. Methods We assembled a panel of pain program directors who serve as officers/board members of the Association of Pain Program Directors, offering guidance and recommendations to pain fellowship directors nationwide. Panel members evaluate the best available evidence and expert opinion on use of remote and virtual platforms in clinical care, adaptability to alterations in clinic and referral management, and provide guidance on postgraduate impact. Conclusions The country is in the midst of an unprecedented pandemic. The impact on pain management fellowships has been significant and will likely last for months, resulting in extraordinary challenges to the administration of pain fellowship programs and the education of our fellows. Several strategies will help address these challenges, including employing telehealth capabilities to continue clinical experiences and providing trainees with opportunities to continue their professional growth beyond fellowship completion. Together, we can implement innovative solutions to overcome these challenges.
Call to action regarding the vascular‐bipolar link: A report from the Vascular Task Force of the International Society for Bipolar Disorders
Goldstein, Benjamin I. , Bond, David J. , Chen, Pao‐Huan , Fagiolini, Andrea , Hájek, Tomáš , Hatch, Jessica, Prieto, Miguel L. , Sylvia, Louisa G. , Tsai, Shang‐Ying , Kcomt, Andrew , Fiedorowicz, Jess G. , Bond, David J , Chen, Pao-Huan , Fagiolini, Andrea , Hajek, Tomas , McIntyre, Roger S , Prieto, Miguel L , Tsai, Shang-Ying , Fiedorowicz, Jess G , Baune, Bernhard , Eyler, Lisa T. , Gomes, Fabiano A. , McElroy, Susan L. , McIntyre, Roger S. , Goldstein, Benjamin I

Mayo Clinic

Bipolar Disorders | May 1, 2020 | Volume: 22 | Issue: 5 | Pages: 440-460

10.1111/bdi.12921 | PMID 32356562 Get It

Abstract Objectives The association of bipolar disorder with early and excessive cardiovascular disease was identified over a century ago. Nonetheless, the vascular‐bipolar link remains underrecognized, particularly with regard to how this link can contribute to our understanding of pathogenesis and treatment. Methods An international group of experts completed a selective review of the literature, distilling core themes, identifying limitations and gaps in the literature, and highlighting future directions to bridge these gaps. Results The association between bipolar disorder and vascular disease is large in magnitude, consistent across studies, and independent of confounding variables where assessed. The vascular‐bipolar link is multifactorial and is difficult to study given the latency between the onset of bipolar disorder, often in adolescence or early adulthood, and subsequent vascular disease, which usually occurs decades later. As a result, studies have often focused on risk factors for vascular disease or intermediate phenotypes, such as structural and functional vascular imaging measures. There is interest in identifying the most relevant mediators of this relationship, including lifestyle (eg, smoking, diet, exercise), medications, and systemic biological mediators (eg, inflammation). Nonetheless, there is a paucity of treatment studies that deliberately engage these mediators, and thus far no treatment studies have focused on engaging vascular imaging targets. Conclusions Further research focused on the vascular‐bipolar link holds promise for gleaning insights regarding the underlying causes of bipolar disorder, identifying novel treatment approaches, and mitigating disparities in cardiovascular outcomes for people with bipolar disorder.
The Role of Antibody Testing for SARS-CoV-2: Is There One?
Theel, Elitza S. , Slev, Patricia, Wheeler, Sarah , Couturier, Marc Roger , Wong, Susan J. , Kadkhoda, Kamran , Wheeler, Sarah E

Mayo Clinic

Journal of Clinical Microbiology | April 29, 2020 | Volume: 58 | Issue: 8 | Pages: No page available

10.1128/jcm.00797-20 | PMID 32350047 Get It

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) brought with it rapid development of both molecular and serologic assays for identification of COVID-19 infections. While Food and Drug Administration (FDA) emergency use authorization (EUA) is required for clinical application of SARS-CoV-2 molecular tests, submission for EUA is currently a voluntary process for manufacturers of serologic assays. The absence of FDA oversight of serologic tests is concerning given that the commercially available serologic assays are highly variable, differing in their format, the antibody class detected, the targeted antigen, and the acceptable specimen types.